Bolt Biotherapeutics, Inc. Deferred Tax Liabilities, Net
Bolt Biotherapeutics, Inc. (BOLT) had Deferred Tax Liabilities, Net of $5.66 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2026-03-12
- 2025-12-31: Deferred Tax Liabilities, Net $5.66M.
- 2024-12-31: Deferred Tax Liabilities, Net $6.51M.
- 2023-12-31: Deferred Tax Liabilities, Net $5.98M.
- 2022-12-31: Deferred Tax Liabilities, Net $7.06M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2025-12-31 | $5.66M 10-K · filed 2026-03-12 |
| 2024-12-31 | $6.51M 10-K · filed 2026-03-12 |
| 2023-12-31 | $5.98M 10-K · filed 2025-03-24 |
| 2022-12-31 | $7.06M 10-K · filed 2024-03-21 |
| 2021-12-31 | $7.64M 10-K · filed 2023-03-29 |
| 2020-12-31 | $3.92M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |